Pathology of triple negative breast cancer

F Borri, A Granaglia - Seminars in cancer biology, 2021 - Elsevier
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …

Tracking cancer evolution through the disease course

C Bailey, JRM Black, JL Reading, K Litchfield… - Cancer discovery, 2021 - AACR
During cancer evolution, constituent tumor cells compete under dynamic selection
pressures. Phenotypic variation can be observed as intratumor heterogeneity, which is …

Simvastatin induced ferroptosis for triple-negative breast cancer therapy

X Yao, R ** the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking
GD Cresswell, D Nichol, I Spiteri, H Tari… - Nature …, 2020 - nature.com
Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high
resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to …

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

JL Caswell-**, K McNamara, JG Reiter, R Sun… - Nature …, 2019 - nature.com
Genomic changes observed across treatment may result from either clonal evolution or
geographically disparate sampling of heterogeneous tumors. Here we use computational …

Effect of neoadjuvant therapy on breast cancer biomarker profile

L Rey-Vargas, JC Mejía-Henao, MC Sanabria-Salas… - BMC cancer, 2020 - Springer
Background Breast cancer clinical management requires the assessment of hormone
receptors (estrogen (ER) and progesterone receptor (PR)), human epidermal growth factor …

Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1

J Li, Y Sun, X Zhi, Y Sun, Z Abudousalamu… - Journal of Ovarian …, 2024 - Springer
Background Lymph node metastasis (LNM) is a major factor contributing to the high mortality
rate of ovarian cancer, making the treatment of this disease challenging. However, the …